Boston-based startup Smartcat has raised $43 million in Series C funding to advance its AI translation platform. Founded just six years ago, Smartcat has served over 1,000 enterprises, including 20% of the Fortune 500 companies. Co-founder and CEO Ivan Smolnikov, a former physicist, aims to disrupt the traditional translation model by providing efficient multilingual content processing. The Smartcat platform supports translation in 280 languages and uses a 'matching engine'.

Abridge announced the completion of $150 million in Series C funding, garnering widespread attention after the launch of ChatGPT, which heightened interest in the clinical documentation field. The funding will impact Abridge's development and challenge competitors, bringing more intelligent solutions to the healthcare industry.

AI21 has announced the completion of its Series C funding, raising $53 million, with a total valuation of $1.4 billion and a total funding amount of $208 million. Amid internal turmoil at OpenAI, AI21 has chosen to announce its funding to compete for market share in generative AI. AI21 emphasizes close collaboration with enterprises, focusing on customization, robustness, and security, offering tailored solutions that differ from OpenAI. AI21 has performed well in the competition, welcoming investments from Intel Capital and Comcast Ventures.

AI pharma company Generate has raised $273 million in funding. The company will use the funds to support drug development in various disease areas, including cancer, infectious diseases, and immunological disorders. Generate utilizes AI to replace trial-and-error methods in drug discovery and to create new protein-based therapies.